Renaissance Technologies’s Aevi Genomic Medicine Inc GNMX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-2,615,632
| Closed | -$382K | – | 4006 |
|
|
2019
Q4 | $382K | Buy |
2,615,632
+223,844
| +9% | +$30.5K | ﹤0.01% | 2988 |
|
|
2019
Q3 | $359K | Buy |
2,391,788
+436,397
| +22% | +$78.8K | ﹤0.01% | 2981 |
|
|
2019
Q2 | $313K | Buy |
1,955,391
+863,474
| +79% | +$175K | ﹤0.01% | 3162 |
|
|
2019
Q1 | $214K | Buy |
1,091,917
+1,027,040
| +1,583% | +$228K | ﹤0.01% | 3195 |
|
|
2018
Q4 | $45K | Buy |
64,877
+36,107
| +126% | +$40.3K | ﹤0.01% | 3295 |
|
|
2018
Q3 | $35K | Buy |
28,770
+3,900
| +16% | +$4.36K | ﹤0.01% | 3299 |
|
|
2018
Q2 | $28K | Sell |
24,870
-28,830
| -54% | -$43.8K | ﹤0.01% | 3207 |
|
|
2018
Q1 | $108K | Sell |
53,700
-39,900
| -43% | -$74.9K | ﹤0.01% | 3255 |
|
|
2017
Q4 | $112K | Buy |
93,600
+78,400
| +516% | +$107K | ﹤0.01% | 3214 |
|
|
2017
Q3 | $19K | Buy |
+15,200
| New | +$19.4K | ﹤0.01% | 3157 |
|
|
2015
Q3 | – | Sell |
-43,408
| Closed | -$266K | – | 3469 |
|
|
2015
Q2 | $266K | Buy |
43,408
+18,208
| +72% | +$141K | ﹤0.01% | 2921 |
|
|
2015
Q1 | $203K | Buy |
+25,200
| New | +$190K | ﹤0.01% | 2883 |
|
|
2013
Q3 | – | Sell |
-15,300
| Closed | -$58K | – | 3013 |
|
|
2013
Q2 | $58K | Buy |
+15,300
| New | +$62.7K | ﹤0.01% | 2683 |
|
Renaissance Technologies's GNMX Position: Q1 2020 in Review
Renaissance Technologies sold out of Aevi Genomic Medicine Inc (GNMX) in Q1 2020, closing a stake of 2,615,632 shares — an estimated $382K sold.
Renaissance Technologies first reported a position in GNMX in Q2 2013 and held it in 13 quarters. The position peaked at $382K in Q4 2019. 2 funds tracked by Wall St. Rank hold GNMX as of Q1 2020.
- Renaissance Technologies reported no remaining Aevi Genomic Medicine Inc position as of Q1 2020 after selling out during the quarter.
- Renaissance Technologies sold 2,615,632 Aevi Genomic Medicine Inc shares in Q1 2020, an estimated $382K.
- Renaissance Technologies first reported a position in Aevi Genomic Medicine Inc in Q2 2013 and held it in 13 quarters.
- Renaissance Technologies's Aevi Genomic Medicine Inc position peaked at $382K in Q4 2019.
- 2 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q1 2020.
Based on Renaissance Technologies's 13F filing for Q1 2020, filed 14 May 2020.